FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Thoracic radiation in combination with erlotinib-results from a phase 2 randomized trial. PMID 39148905 · Front Oncol · 2024 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Music Therapy and Music Intervention for NSCLC Patients Undergoing PET with Fear of Cancer Recurrence. PMID 39135426 · Integr Cancer Ther · 2024 The trial is a randomized, controlled, oncology study in humans with an original primary result. However, it is not a Phase III or definitive trial (phase not specified, likely Phase II or unspecified), it does not have a time-to-event efficacy endpoint (primary outcome is PET scan glucose metabolism; secondary outcomes are anxiety scores and biomarkers), and it does not involve a drug-containing intervention (music therapy is non-drug). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Robot-assisted radical nephroureterectomy using the KangDuo Surgical Robot-01 System versus the da Vinci System: a multicenter prospective randomized controlled trial. PMID 39133792 · Int Braz J Urol · 2024 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| The impact of inhalation versus total intravenous anesthesia on the immune status in patients undergoing breast cancer surgery: a double-blind randomized clinical trial (TeMP). PMID 39132502 · Front Oncol · 2024 The study is a randomized trial in breast cancer patients but is Phase II/III unclear, uses anesthesia agents (not systemic oncology drugs), and assesses immune and inflammatory biomarkers (NLR, CRP, etc.) as primary/secondary endpoints, not time-to-event efficacy outcomes. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Randomized experimental population-based study to evaluate the acceptance and completion of and preferences for cervical cancer screening. PMID 39121102 · PLoS One · 2024 The study is randomized and human, but it evaluates acceptance and completion of screening methods (Pap, self-collection), not a drug-containing intervention. No time-to-event efficacy endpoints (OS, PFS, etc.) or Kaplan-Meier analysis are reported. It is not a Phase III/IIIb or Phase II/III randomized trial of a drug intervention. Therefore, it does not meet the inclusion criteria for the oncology KM digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Randomized, Multi-Center, Open Label Study to Compare the Safety and Efficacy between Afatinib Monotherapy and Combination Therapy with HAD-B1 for the Locally Advanced or Metastatic NSCLC Patients with EGFR Mutations. PMID 39103991 · Integr Cancer Ther · 2024 The record describes a randomized trial with drug intervention and time-to-event endpoints, but the phase of the trial is not explicitly established in the provided metadata (title, abstract, publication types, or mesh). Eligibility requires explicit evidence of Phase III/IIIb or Phase II/III status. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A systematic review and meta-analysis on utilizing anti-CD19 chimeric antigen receptor T-cell therapy as a second-line treatment for relapsed and refractory diffuse large B-cell lymphoma. PMID 39091918 · Front Oncol · 2024 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Oral Decoctions Based on Qi-Yin Syndrome Differentiation After Adjuvant Chemotherapy in Resected Stage ΙΙΙA Non-Small Cell Lung Cancer: A Randomized Controlled Trial. PMID 39081216 · Integr Cancer Ther · 2024 The study meets criteria for oncology, human, randomized, drug intervention, and time-to-event endpoint. However, the trial phase is not explicitly established as Phase III/IIIb or Phase II/III in the provided record, which is a required criterion for eligibility under the specified protocol. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trial. PMID 39072392 · Future Oncol · 2024 未发现恶性肿瘤人群证据。 |
H
L
B
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Combination Therapy with Immune Checkpoint Inhibitors and Histone Deacetylase Inhibitors or Alkylating Agents. PMID 39072340 · Cancer Manag Res · 2024 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Assessing Fidelity in Yoga Interventions for Chemotherapy-Induced Peripheral Neuropathy: Decision-Making to Enhance Protocol Quality Adherence. PMID 39066651 · Integr Cancer Ther · 2024 The record is a methodological article about fidelity monitoring for an ongoing trial. It does not contain the formal, primary results of the trial's efficacy analysis with a time-to-event endpoint. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Evaluation of ex vivo drug combination optimization platform in recurrent high grade astrocytic glioma: An interventional, non-randomized, open-label trial protocol. PMID 39058662 · PLoS One · 2024 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Yiqi Wenyang Jiedu prescription for preventing and treating postoperative recurrence and metastasis of gastric cancer: a randomized controlled trial protocol. PMID 39035732 · Front Oncol · 2024 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Comparison of the Efficacy, Safety, and Quality of Life of Pegylated Liposomal Doxorubicin-Cyclophosphamide versus Epirubicin-Cyclophosphamide in Patients with Early-Stage HER2-Negative Breast Cancer: A Prospective, Randomized, Multicenter, Phase II Study. PMID 39033747 · Oncol Res Treat · 2024 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF). PMID 39015176 · Front Endocrinol (Lausanne) · 2024 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Plain language summary of PAPILLON: amivantamab plus chemotherapy in untreated EGFR-mutated non-small-cell lung cancer. PMID 39012623 · Future Oncol · 2024 The provided record is a plain language summary without an abstract or full text, and no signals for time-to-event endpoints (OS, PFS, DFS, EFS, RFS, TTP, KM curves, or HR) are present. While it appears oncology and drug-related, the lack of clear human trial, randomized design, phase, and primary result data prevents eligibility. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| A clinician's perspective on boron neutron capture therapy: promising advances, ongoing trials, and future outlook. PMID 38986056 · Int J Radiat Biol · 2024 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Investigating the effects of cytokine biomarkers on HIV incidence: a case study for individuals randomized to pre-exposure prophylaxis vs. control. PMID 38983264 · Front Public Health · 2024 The study is a randomized controlled trial with a drug intervention (PrEP) and time-to-event efficacy endpoint (HIV incidence) analyzed with Kaplan-Meier and Cox PH models. However, it is not an oncology study, as it focuses on HIV prevention, not human malignant neoplasm. Therefore, it is excluded based on the non-oncology criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| High-intensity focused ultrasound ablation combined with immunotherapy for treating liver metastases: A prospective non-randomized trial. PMID 38968190 · PLoS One · 2024 This is a prospective, non-randomized, single-arm trial evaluating safety and feasibility. It is not a Phase III/IIIb or Phase II/III randomized trial. The primary endpoint is safety/feasibility, not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Surgical myomectomy followed by oral Myfembree vs standard of care (SOUL trial): Study protocol for a randomized control trial. PMID 38954680 · PLoS One · 2024 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade. PMID 38952672 · Oncoimmunology · 2024 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Cardiotoxicity of CPX-351 in children and adolescents with relapsed AML: a Children's Oncology Group report. PMID 38947228 · Front Cardiovasc Med · 2024 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| [Pharmacological properties and clinical development overview of pertuzumab (genetical recombination), trastuzumab (genetical recombination) and vorhyaluronidase alfa (genetical recombination) (PHESGO® combination for subcutaneous injection MA, IN)]. PMID 38945908 · Nihon Yakurigaku Zasshi · 2024 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Clinical Efficacy of Yiqi Yangyin Decoction Combined with Adjuvant Chemotherapy on the Postoperative Life Quality of Breast Cancer. PMID 38909291 · Nutr Cancer · 2024 The study is a randomized, oncology trial with a drug intervention and a time-to-event endpoint, but the trial phase is not explicitly confirmed as Phase III/IIIb or Phase II/III, and the primary focus appears to be on quality of life rather than a formal time-to-event efficacy analysis. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparison of the clinical effectiveness of hepaticojejunostomy and self-expanding metal stents for bypassing the bile ducts in patients with unresectable pancreatic head cancer complicated by obstructive jaundice. PMID 38865614 · Wiad Lek · 2024 The record describes a randomized comparative study in oncology (pancreatic cancer) with human subjects and original results. However, it is not eligible because it does not meet key criteria: 1) The phase is not established as Phase III or definitive Phase II/III; 2) No primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier curve, or HR) is reported; outcomes focus on procedural complications and short-term morbidity, not survival or progression. 3) The intervention is a surgical procedure (hepaticojejunostomy) vs. a device (self-expanding metal stents), not a drug-containing intervention. The study is a randomized trial of palliative procedures for obstructive jaundice, not an efficacy trial of a cancer drug. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| COMPANION-002 A clinical trial of investigational drug CTX-009 plus paclitaxel vs paclitaxel in second line advanced BTC. PMID 38861293 · Future Oncol · 2024 This is a protocol abstract for a randomized phase II/III oncology trial with a drug intervention, but it does not report results. The primary endpoint is ORR (objective response rate), which is not a time-to-event endpoint. No time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP), Kaplan-Meier analysis, or hazard ratio is reported or even mentioned as a primary/secondary endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of anti-angiogenic drug monotherapy and combination therapy for ovarian cancer: a meta-analysis and trial sequential analysis of randomized controlled trials. PMID 38860165 · Front Pharmacol · 2024 The record is a meta-analysis, which synthesizes results from multiple RCTs. It is not an original, formal-result report of a single Phase III/IIIb or Phase II/III randomized trial. Therefore, it does not meet the inclusion criteria for an original trial result. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparative effectiveness of primary tumor resection versus chemotherapy in patients with asymptomatic unresectable metastatic colorectal cancer: a retrospective cohort study using the target trial emulation framework. PMID 38859829 · Am J Cancer Res · 2024 This is a retrospective cohort study using target trial emulation and includes a meta-analysis. It is not a report of an original Phase III/IIIb or Phase II/III randomized trial. The study is observational and does not present results from a single definitive randomized trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A pharmacist-led interprofessional medication adherence program improved adherence to oral anticancer therapies: The OpTAT randomized controlled trial. PMID 38848380 · PLoS One · 2024 Eligibility requires an explicitly established Phase III/IIIb or Phase II/III trial. The provided record describes a randomized, oncology trial with drug intervention and a time-to-event endpoint, but the trial phase is not explicitly stated in the title, abstract, or metadata, so it cannot be confirmed as meeting the phase criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Modulatory Effects of XIAOPI Formula on CXCL1 and Selected Outcomes in Triple-Negative Breast Cancer: A Randomized Controlled Clinical Trial. PMID 38835647 · Breast Cancer (Dove Med Press) · 2024 The trial is oncology-focused, human, randomized, has a drug intervention (XIAOPI formula), and reports original results. However, it lacks a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) as required. The primary and secondary outcomes are biomarker (CXCL1), quality-of-life, and psychological measures, not survival or time-to-event metrics. Also, the phase is not specified as Phase III/IIIb; it appears to be an early-phase or unspecified randomized trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effects of a Tai Chi rehabilitation program implemented using a hybrid online and offline mode on oxidative stress and inflammatory responses in patients with coronary heart disease: a randomized controlled trial. PMID 38827614 · Front Public Health · 2024 The study is a randomized controlled trial but is not an oncology study (focuses on coronary heart disease), does not involve a drug-containing intervention (uses exercise rehabilitation), and lacks a time-to-event efficacy endpoint (measures biomarkers, not survival or progression outcomes). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| [Current state of graft-versus-host disease prophylaxis with PTCy for allogeneic hematopoietic stem cell transplantation]. PMID 38825519 · Rinsho Ketsueki · 2024 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Effect of pentoxifylline on endothelial dysfunction, oxidative stress and inflammatory markers in STEMI patients. PMID 38817362 · Future Sci OA · 2024 The study is a randomized trial of pentoxifylline in STEMI patients (non-oncology), with biomarker endpoints, not a time-to-event efficacy endpoint (OS, PFS, etc.). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The role of platelet rich plasma enriched fat graft for correction of deformities after conservative breast surgery. PMID 38758987 · Breast Dis · 2024 Study is an oncology RCT but fails key eligibility criteria: it is not a drug-intervention trial (evaluates PRP-enriched fat grafting, a surgical/technical procedure) and lacks a time-to-event efficacy endpoint. Phase is not specified. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| SupporTive Care At Home Research (STAHR) for patients with advanced cancer: Protocol for a cluster non-randomized controlled trial. PMID 38739589 · PLoS One · 2024 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Assessment of safety and tolerability of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: Results of an open-label, randomized, multicenter, phase IIIB ESCAPE trial. PMID 38735220 · Cancer Treat Res Commun · 2024 The study is a Phase IIIb randomized trial with a drug intervention (trastuzumab) and reports original results. However, its primary focus and reported outcomes are safety, tolerability, administration time, and patient preference. There is no mention of a time-to-event efficacy endpoint such as overall survival (OS), progression-free survival (PFS), disease-free survival (DFS), event-free survival (EFS), recurrence-free survival (RFS), time to progression (TTP), Kaplan-Meier analysis, or hazard ratio (HR). Therefore, it does not meet the required inclusion of a primary/key secondary time-to-event efficacy endpoint. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The efficacy of coaxial percutaneous iodine-125 seed implantation combined with arterial infusion chemotherapy for advanced pancreatic cancer: a randomized clinical trial. PMID 38687687 · Int J Radiat Biol · 2024 The record describes a randomized clinical trial in advanced pancreatic cancer with a drug-containing intervention (arterial infusion chemotherapy) and a primary time-to-event efficacy endpoint (survival time). However, the trial phase is not explicitly stated in the provided metadata as Phase III/IIIb or Phase II/III, and it cannot be inferred from the drug name or other available information. Therefore, eligibility cannot be confirmed. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Dexmedetomidine Pretreatment Confers Myocardial Protection and Reduces Mechanical Ventilation Duration for Patients Undergoing Cardiac Valve Replacement under Cardiopulmonary Bypass. PMID 38684422 · Ann Thorac Cardiovasc Surg · 2024 The study is a randomized controlled trial evaluating dexmedetomidine for myocardial protection during cardiac surgery. It is not an oncology study, does not involve human malignant neoplasms, and reports only physiological and procedural outcomes (e.g., cardiac biomarkers, mechanical ventilation duration) without any time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier curves, or HR). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Treatment with nanosomal paclitaxel lipid suspension versus conventional paclitaxel in metastatic breast cancer patients - a multicenter, randomized, comparative, phase II/III clinical study. PMID 38680290 · Ther Adv Med Oncol · 2024 The study is a randomized phase II/III trial with a drug intervention and reports original results, but its primary endpoint is overall response rate (ORR), a response-based endpoint, not a time-to-event endpoint such as OS, PFS, DFS, EFS, RFS, TTP, or a Kaplan-Meier/HR analysis. Therefore, it does not meet the requirement for a primary/key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparison between use of a pleural drainage system with flutter valve and a conventional water-seal drainage system after lung resection: a randomized prospective study. PMID 38655983 · Sao Paulo Med J · 2024 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Progressive relaxation training in patients with breast cancer receiving aromatase inhibitor therapy-randomized controlled trial. PMID 38635763 · PLoS One · 2024 The trial is randomized and involves a drug intervention (aromatase inhibitors) in oncology, but it does not have a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The endpoints are pain severity, quality of life, and emotional status, which are not time-to-event outcomes. Additionally, the trial phase is not explicitly stated as Phase III/IIIb or definitive Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Protocol for a phase II study to evaluate the efficacy and safety of nivolumab as a postoperative adjuvant therapy for patients with esophageal cancer treated with preoperative docetaxel, cisplatin plus 5-fluorouracil treatment (PENTAGON trial). PMID 38635652 · PLoS One · 2024 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Patient-Controlled Subcutaneous Analgesia with Hydromorphone versus Oral Oxycontin for Opioid Titration of Cancer Pain: A Prospective Multicenter Randomized Trial. PMID 38628430 · J Pain Res · 2024 The study is a randomized trial comparing two analgesic regimens for cancer pain titration. While it involves human cancer patients and drug interventions, the primary endpoint (time to successful titration) is a pain management outcome, not a standard oncology time-to-event efficacy endpoint like OS, PFS, or DFS. Therefore, it does not meet the criteria for inclusion in an oncology Kaplan-Meier digitization cohort focusing on treatment efficacy. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of PARP inhibitors combined with antiangiogenic agents in the maintenance treatment of ovarian cancer: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials. PMID 38584601 · Front Pharmacol · 2024 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Effectiveness of sigmoidoscopy or colonoscopy screening on colorectal cancer incidence and mortality: a systematic review and meta-analysis of randomized controlled trial. PMID 38549924 · Front Oncol · 2024 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen. PMID 38547003 · Future Oncol · 2024 The record is a patient education handout about the TRANSFORM study, not a primary formal clinical trial result report. While the topic is oncological and involves a human drug intervention, the publication type, lack of explicit time-to-event endpoint reporting in the provided metadata, and absence of confirmed randomization and phase details prevent eligibility. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Erector Spinae Plane Block versus Quadratus Lumborum Block for Postoperative Analgesia after Laparoscopic Resection of Colorectal Cancer: A Prospective Randomized Study. PMID 38529324 · Anesthesiol Res Pract · 2024 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| A Novel Validated Real-World Dataset for the Diagnosis of Multiclass Serous Effusion Cytology according to the International System and Ground-Truth Validation Data. PMID 38522415 · Acta Cytol · 2024 This is a validation study for an AI diagnostic tool in serous effusion cytology, not a randomized clinical trial. It does not involve a drug intervention or a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Add-on effects of Chinese herbal medicine external application (FZHFZY) to topical urea for mild-to-moderate psoriasis vulgaris: Protocol for a double-blinded randomized controlled pilot trial embedded with a qualitative study. PMID 38512933 · PLoS One · 2024 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| A randomised controlled trial of Pre-Operative Oncotype DX testing in early-stage breast cancer (PRE-DX study) - Study protocol. PMID 38489298 · PLoS One · 2024 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |